CytoHub 2024: A Year of Transformative Milestones, Unstoppable Growth, and Bold Visions for the Future

Rajib Biswas, PhD

CEO & Co-Founder | Regenerative Medicine | Stanford GSB | Dad

Published Dec 25, 2024

2024 has been a landmark year for CytoHub Inc. —a biotechnology company based in San Diego, CA [JLABS @ San Diego]—dedicated to pioneering transformative cellular therapeutics for heart muscle regeneration. After two decades in biotechnology, and almost 10 years in cell therapy and regenerative medicine, I thought I had seen it all. But 2024 surprised me in ways I couldn’t have imagined. This year, our work at CytoHub Inc. —pioneering cellular therapeutics and leveraging AI to advance regenerative medicine—has been both exhilarating and groundbreaking. As we reflect on the journey, it’s clear that our mission to address the vast unmet medical need in heart failure has driven us to achieve extraordinary milestones, making this year one of innovation, impact, and bold steps toward the future.

CytoHub Inc. is an integrated biotechnology company established with the “stealth” mission of developing medicines to address the significant unmet medical need in heart failure patients, particularly through the development of cellular therapeutics for heart muscle regeneration.

Heart attack leads cell death to lifelong heart failure

Since our inception in 2023, we enabled cell-based therapeutics to rapidly grow into a revenue-generating company operating in the prestigious JLABS @ San Diego. Leveraging our deep knowledge of process engineering, scale-up, and manufacturing of cell-based drug candidates, we have implemented state-of-the-art technologies and bespoke AI-based platform to accelerate drug development. We have also quietly assembled a world-class team, unique assets, and technology that will enable us to pursue our mission of developing cures for heart failure.

The CytoHub Platform Quadrant

Four pillars driving innovation in cardiac regeneration revolutionizing through cutting-edge technology:

CardioVive™: Human mini-heart platform for therapeutic screening and drug discovery
HeartReady™: Cryopreserved, off-the-shelf iPSC-derived cardiomyocytes as therapeutic candidate
CytoScale™: Scale-up solutions powered by AI and world-class expertise
BioEngineAI™: An AI-driven platform enhancing cellular therapy and drug development

— these four pillars collectively define CytoHub’s approach to pioneering regenerative therapies, with the ultimate goal of transforming the lives of heart failure patients worldwide.

Revolutionizing Heart Failure Treatment

Heart failure remains one of the leading causes of death globally, with limited treatment options for millions. At CytoHub Inc. , we’re not just imagining a world where heart failure is reversible—we’re building it. Inspired by personal loss and professional purpose, I am honored to lead a team of world-class scientists, engineers, and biotech leaders in developing cutting-edge regenerative therapies that rebuild damaged heart muscle.

HeartReady™: Using human iPSC-derived cardiomyocytes—our "mini hearts"—we’ve created proprietary technologies that enhance physiological performance, scalability, and therapeutic impact. By integrating advanced stem cell biology with AI-powered engineering, we are developing innovative solutions like HeartReady™, our off-the-shelf cellular therapy.

HeartReady™ – Cryopreserved, off-the-shelf iPSC-derived cardiomyocytes as therapeutic candidate

CardioVive™: The company’s PSC-derived human mini-heart technology platform, that functionally and physiologically emulates 96% of human heart morphology and physiology, and includes cells forming atrial and ventricular chambers, endothelial networks, cardiac macrophages, and all cardiac cell types with physiologically relevant distribution and ratios.

Cardiac action potential analysis on mini-hearts using MEA with IntraCell to study arrhythmia using

There is no comparable model known at this time. While our platform offers unrivalled potential for cardiac disease modeling and drug screening, our primary mission is to leverage the platform to develop our HeartReady™ regenerative cell therapies for heart muscle regeneration.

CardioVive™ – Human mini-heart platform for therapeutic screening and drug discovery

Transformative Milestones in 2024

This year, CytoHub Inc. has expanded its capabilities and vision through:

Proprietary Innovation: With state-of-the-art AI platforms like BioEngineAI™ and CytoScale™, we’re solving critical bottlenecks in cell therapy manufacturing, enabling scalable, efficient production of iPSC-derived cardiomyocytes.
BioEngineAI™: A machine learning architecture for integrated semantic analysis of multimodal data

BioEngineAI™ – An AI-driven platform enhancing cellular therapy and drug development

CytoGPT™: Our first BioEngineAI™ application- its technology is based on state-of-the-art large language models (LLMs) such as Google Gemini, Meta Llama 2 and Mistral-7B. CytoGPT™ has been trained with knowledge from PubMed (with over 10.1 million articles) and fine-tuned with our proprietary data. CytoGPT™ focuses on data relevant to our drug development. CytoGPT™ was built with the goal of revolutionizing the way research is conducted: 1) Enhanced accuracy and precision in retrieving and analyzing biological data. 2) Efficient hypothesis generation and experiment design. 3) Streamlined integration of diverse data sources. 4) Predictive capabilities and novel recommendations on potential research approaches and ideas.
CytoVision™: A novel AI-powered tool developed by CytoHub Inc. as part of the BioEngineAI™ suite to enhance the development of cell therapy and regenerative medicine drug products.

CytoVision™ – a novel AI-powered tool developed by @CytoHub as part of the BioEngineAI™ suit

A Stellar Team: Our team’s expertise spans cardiac cell therapy at UW Institute for Stem Cell and Regenerative Medicine , UW Medicine + Heart Institute / UW Medicine (Cytocardia), Sana Biotechnology, Inc. , clinical development at Pfizer , Vertex Pharmaceuticals , Fate Therapeutics Inc. , Resilience , and AI & Machine Learning at Oracle , Yahoo , Chime , Stanford University , UC Santa Barbara , UC San Diego , business leaders from Stanford University Graduate School of Business . Graduates and professionals from Stanford University , Massachusetts Institute of Technology , Salk Institute for Biological Studies , Cornell University , University of Oxford , Michigan State University , and Imperial College London are at the heart of our success.

CytoHub Inc.: Leadership team with 100+ years of combined domain expertise

Strategic Growth: We've completed readiness to initiate our $11.5M seed funding round to accelerate the development of our flagship product, HeartReady™, aiming to redefine the standard of care for heart failure. This funding will enable us to:

- Complete pre-clinical development.

- Generate non-human primate (NHP) data.

- Establish a physician network.

- Achieve IND readiness.

A Vision for Impact: Our bold goal is to capture a share of the $8.5B heart failure treatment existing market (2023), create a potential new market of tens of billions (e.g. 6.7M patients in the US alone with heart failure), becoming the global leader in regenerative cardiac medicine.

Unmatched Expertise and a Bold Vision

CytoHub Inc. ’s mission is more than a scientific endeavor; it’s a commitment to saving lives and redefining what’s possible in cardiac care. With over 100 years of combined industry experience, our team is uniquely positioned to deliver life-saving therapies that repair heart tissue, improve cardiac function, and restore vitality for millions of patients.

Our purpose is deeply personal. Driven by my father’s battle with heart disease, has devoted my career to heart regeneration. My journey—from manufacturing hundreds of billions of cardiomyocytes from embryonic stem cells at UW Medicine/ Cytocardia, Sana Biotechnology to founding CytoHub Inc. in 2023—embodies the spirit of innovation and compassion that defines our company.

Building the Future of Medicine Together

At CytoHub Inc. , we believe that innovation thrives at the intersection of collaboration and vision. That’s why we’re inviting strategic partners, visionary investors, and passionate collaborators to join us on this journey. With the potential to transform how heart failure is treated, we’re not just building a company; we’re leading a movement.

Celebrating the People Who Make It Possible

None of our achievements in 2024 would have been possible without the incredible people behind CytoHub Inc. From scientists pushing the boundaries of cell biology to engineers crafting scalable solutions, every member of our team embodies the spirit of purpose-driven innovation.

We also extend heartfelt thanks to our early collaborators, mentors, and advisors. Their trust, feedback, and shared commitment to advancing regenerative medicine have been invaluable.

Looking Ahead to 2025 ❤️

As we close 2024, we’re energized by our progress and excited for the future. The challenges of heart failure are vast, but so are the opportunities to make a difference. With our innovative technologies, exceptional team, and unwavering commitment, CytoHub Inc. is poised to revolutionize cardiac care and deliver transformative impact for patients worldwide.

Together, we’re building a future where heart failure is no longer a life sentence but a condition that regenerative medicine can cure. The best is yet to come. ❤️